Adverum Biotechnologies Provides Update on Alpha-1 Antitrypsin Deficiency Program
Oct 14, 2016 11:01 am UTC| Business
MENLO PARK, Calif., Oct. 14, 2016 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM) today provided an update on its development program for ADVM-043 (formerly “ANN-001”), a novel gene therapy for Alpha-1 Antitrypsin (A1AT)...
Adverum Biotechnologies, Inc. Announces New Executive Chair and CEO
Oct 14, 2016 11:00 am UTC| Business
Paul Cleveland Named Executive Chairman of the Board Amber Salzman, Ph.D. Named CEO MENLO PARK, Calif., Oct. 14, 2016 -- Adverum Biotechnologies, Inc. (Nasdaq:ADVM), a gene therapy company committed to...
Intellia Therapeutics to Present Data at the European Society of Gene & Cell Therapy Congress
Oct 14, 2016 11:00 am UTC| Business
CAMBRIDGE, Mass., Oct. 14, 2016 -- Intellia Therapeutics, Inc. (NASDAQ:NTLA),a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that...
Broadwind To Announce Q3 2016 Results on October 28
Oct 14, 2016 11:00 am UTC| Business
CICERO, Ill., Oct. 14, 2016 -- Broadwind Energy, Inc. (NASDAQ:BWEN) will announce third quarter 2016 results on Friday, October 28, 2016 before market open. An investor conference call will follow at 10 a.m. Central...
Akari Therapeutics Appoints New Members to its Board of Directors
Oct 14, 2016 11:00 am UTC| Business
NEW YORK and LONDON, Oct. 14, 2016 -- Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, announced today the appointment of Robert Ward to its Board of Directors. Mr. Ward...
UroGen Pharma Announces Agreement to License RTGel™ for Use with Neurotoxins to Allergan
Oct 14, 2016 11:00 am UTC| Business
RAANANA, Israel, Oct. 14, 2016 -- UroGen Pharma (“UroGen”), a privately-held, clinical-stage biotechnology company, announced today that it has completed an agreement to license worldwide rights to UroGen’s RTGelTM...
MVC Capital Declares Quarterly Dividend
Oct 14, 2016 10:55 am UTC| Business
PURCHASE, N.Y., Oct. 14, 2016 -- MVC Capital, Inc.(NYSE:MVC), a publicly traded business development company that makes private debt and equity investments, announced today that its board of directors has declared a...